- The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trialBai, L.; Bai, Y.; Huang, M.; Shao, G.; Song, L.; Sun, M.; Wang, W.; Wu, J.; Xu, A.; Huang, L.; Liu, T.; Liu, W.; Wang, Z. M.; Li, B.; Xia, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.Ren, Zhenggang; Guo, Yabing; Bai, Yuxian; Ying, Jieer; Meng, Zhiqiang; Chen, Zhendong; Gu, Shanzhi; Zhang, Jingdong; Liang, Jun; Hou, Xinfang; Li, Wei; Xu, Aibing; Hao, Chunyi; Zhang, Jian; Xing, Ruijun; Zhang, Xinyu; Zhang, Dan; Chan, Stephen LamGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.被引 3
- Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).Zhao, Hong; Zhou, Aiping; Tu, Jianfei; Bai, Yuxian; Mao, Xianhai; Song, Tianqiang; Li, Bo; Dai, Wenxiang; Lv, Jing; Wang, Jufeng; Che, Xu; Liu, Lianxin; Zhang, Lianhai; Wu, Wei; Cai, JianqiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results.
1被引11阅读
